Biosplice's lorecivivint, an intra-articular small-molecule injection given as infrequently as once yearly, has entered formal review with the UK's MHRA, with an EU filing to follow. Phase 3 OA-07 data showed maintained or improved medial joint space width over two years, alongside pain and function gains by six to twelve months, positioning it as the first candidate aimed at joint structure rather than symptom suppression in knee osteoarthritis.
Key Points
- MHRA accepted lorecivivint application; EU filing planned this month
- Joint space width maintained or improved over two years
- Dual DYRK1A and CLK2 inhibition targets inflammation and cartilage repair
Longevity Analysis
Osteoarthritis erodes healthspan less through cartilage measurements than through the withdrawal from movement that follows — and declining mobility predicts frailty, metabolic deterioration and mortality with uncomfortable reliability. A therapy that preserves joint architecture rather than masking nociceptive signaling addresses the cause of that withdrawal, protecting the structural capacity that sustains circulation, energy production and independence across decades. Localized delivery limits systemic exposure, which matters for anyone weighing long-term intervention against cumulative pharmacological burden on detoxification pathways.
Original published by Longevity.Technology, by Kyle Umipig.